TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Avadel Pharmaceuticals ( (AVDL) ) has issued an update.
On December 8, 2025, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired for the acquisition of Avadel Pharmaceuticals by Alkermes, marking a significant step towards finalizing the transaction. The acquisition, structured as a scheme of arrangement, still requires customary closing conditions, including shareholder approval and court sanction, which could impact Avadel’s market position and stakeholder interests.
The most recent analyst rating on (AVDL) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
Spark’s Take on AVDL Stock
According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.
Avadel Pharmaceuticals’ overall stock score is driven by strong corporate events and positive technical indicators. However, the company’s financial performance is hindered by profitability challenges, and its valuation is impacted by a negative P/E ratio. The stock shows potential for growth, supported by strategic corporate actions and positive market momentum.
To see Spark’s full report on AVDL stock, click here.
More about Avadel Pharmaceuticals
Avadel Pharmaceuticals is a public limited company incorporated under the laws of Ireland, operating in the pharmaceutical industry. The company focuses on developing and commercializing pharmaceutical products, with a market emphasis on innovative treatments.
Average Trading Volume: 2,906,182
Technical Sentiment Signal: Buy
Current Market Cap: $2.09B
Find detailed analytics on AVDL stock on TipRanks’ Stock Analysis page.